Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diazepam derivatives | 2614 | 10379-14-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
None
None
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,EIF2AK3,GRK2,MAPK7,PDK1,PDK2,PDK4 | 7 | |||
| kinase-selectivity-class | EIF2AK3,GRK2,TTK | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cross sensitivity reaction | 94.48 | 38.14 | 19 | 1530 | 2838 | 90624060 |
| Dermatitis contact | 83.08 | 38.14 | 23 | 1526 | 13572 | 90613326 |
| Occupational exposure to product | 61.27 | 38.14 | 13 | 1536 | 2518 | 90624380 |
| Eczema | 55.78 | 38.14 | 24 | 1525 | 52846 | 90574052 |
| Skin test positive | 54.82 | 38.14 | 10 | 1539 | 890 | 90626008 |
| Eczema eyelids | 49.43 | 38.14 | 8 | 1541 | 350 | 90626548 |
| Junctional ectopic tachycardia | 45.69 | 38.14 | 7 | 1542 | 214 | 90626684 |
| Paranasal sinus inflammation | 44.80 | 38.14 | 8 | 1541 | 631 | 90626267 |
| Sinobronchitis | 44.06 | 38.14 | 8 | 1541 | 693 | 90626205 |
| Wrong technique in product usage process | 42.93 | 38.14 | 22 | 1527 | 71549 | 90555349 |
| Osteoporosis postmenopausal | 42.03 | 38.14 | 7 | 1542 | 366 | 90626532 |
| Peripheral nerve lesion | 40.31 | 38.14 | 7 | 1542 | 470 | 90626428 |
| Foramen magnum stenosis | 39.18 | 38.14 | 6 | 1543 | 183 | 90626715 |
| Radial nerve palsy | 38.58 | 38.14 | 7 | 1542 | 604 | 90626294 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Logorrhoea | 105.95 | 63.21 | 20 | 550 | 2787 | 42617978 |
| Transposition of the great vessels | 94.25 | 63.21 | 14 | 556 | 451 | 42620314 |
| Vestibular disorder | 81.26 | 63.21 | 14 | 556 | 1163 | 42619602 |
| Toxicity to various agents | 77.81 | 63.21 | 44 | 526 | 229092 | 42391673 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 116.34 | 36.15 | 68 | 1081 | 480487 | 110107663 |
| Logorrhoea | 99.46 | 36.15 | 20 | 1129 | 4937 | 110583213 |
| Dermatitis contact | 93.91 | 36.15 | 23 | 1126 | 13930 | 110574220 |
| Cross sensitivity reaction | 91.31 | 36.15 | 19 | 1130 | 5548 | 110582602 |
| Occupational exposure to product | 82.08 | 36.15 | 13 | 1136 | 826 | 110587324 |
| Vestibular disorder | 73.45 | 36.15 | 14 | 1135 | 2618 | 110585532 |
| Skin test positive | 55.05 | 36.15 | 10 | 1139 | 1439 | 110586711 |
| Eczema eyelids | 52.01 | 36.15 | 8 | 1141 | 419 | 110587731 |
| Psychomotor skills impaired | 49.31 | 36.15 | 12 | 1137 | 7046 | 110581104 |
| Wrong technique in product usage process | 49.24 | 36.15 | 22 | 1127 | 87326 | 110500824 |
| Disturbance in attention | 42.72 | 36.15 | 18 | 1131 | 61977 | 110526173 |
| Coordination abnormal | 42.04 | 36.15 | 14 | 1135 | 25214 | 110562936 |
| Agoraphobia | 40.96 | 36.15 | 7 | 1142 | 709 | 110587441 |
| Suicide attempt | 39.71 | 36.15 | 20 | 1129 | 103374 | 110484776 |
| Eczema | 36.90 | 36.15 | 17 | 1132 | 72276 | 110515874 |
None
| Source | Code | Description |
|---|---|---|
| ATC | M03BX07 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Other centrally acting agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D009125 | Muscle Relaxants, Central |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
None
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.8 | Basic |
None
None
None
| ID | Source |
|---|---|
| D07277 | KEGG_DRUG |
| C5831153 | UMLSCUI |
| CHEBI:135198 | CHEBI |
| CHEMBL2105527 | ChEMBL_ID |
| DB13324 | DRUGBANK_ID |
| C005245 | MESH_SUPPLEMENTAL_RECORD_UI |
| 25215 | PUBCHEM_CID |
| 2182 | INN_ID |
| FO92091VP8 | UNII |
| 37985 | RXNORM |
| 005346 | NDDF |
| 698845008 | SNOMEDCT_US |
None